110 related articles for article (PubMed ID: 25831767)
1. [HDAC inhibitor].
Saijo K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():277-80. PubMed ID: 25831767
[No Abstract] [Full Text] [Related]
2. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
Rangwala S; Zhang C; Duvic M
Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
[TBL] [Abstract][Full Text] [Related]
3. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma.
Lopez AT; Bates S; Geskin L
Am J Clin Dermatol; 2018 Dec; 19(6):805-819. PubMed ID: 30173294
[TBL] [Abstract][Full Text] [Related]
4. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Duvic M
Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
Epping MT; Bernards R
Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
[TBL] [Abstract][Full Text] [Related]
6. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?
Petta V; Gkiozos I; Strimpakos A; Syrigos K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.
Wu CH; Yang CY; Wang L; Gao HX; Rakhshandehroo T; Afghani S; Pincus L; Balassanian R; Rubenstein J; Gill R; Bandyopadhyay S; McCormick F; Moasser M; Ai WZ
J Invest Dermatol; 2021 Feb; 141(2):364-373. PubMed ID: 32603749
[TBL] [Abstract][Full Text] [Related]
8. Proteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells.
Xu S; Ren J; Lewis JM; Carlson KR; Girardi M
J Invest Dermatol; 2023 Jul; 143(7):1322-1325.e3. PubMed ID: 36642402
[No Abstract] [Full Text] [Related]
9. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.
Giannini G; Cabri W; Fattorusso C; Rodriquez M
Future Med Chem; 2012 Jul; 4(11):1439-60. PubMed ID: 22857533
[TBL] [Abstract][Full Text] [Related]
10. Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications.
Thaler F
Pharm Pat Anal; 2012 Mar; 1(1):75-90. PubMed ID: 24236715
[TBL] [Abstract][Full Text] [Related]
11. We should have a dream: unlocking the workings of the genome in cutaneous T-cell lymphomas.
Porcu P; Wong HK
Clin Lymphoma Myeloma; 2009 Dec; 9(6):409-11. PubMed ID: 19951878
[No Abstract] [Full Text] [Related]
12. Histone deacetylase 10, a potential epigenetic target for therapy.
Cheng F; Zheng B; Wang J; Zhao G; Yao Z; Niu Z; He W
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 33997894
[TBL] [Abstract][Full Text] [Related]
13. Emerging role of epigenetic therapies in cutaneous T-cell lymphomas.
Zain J; Kaminetzky D; O'Connor OA
Expert Rev Hematol; 2010 Apr; 3(2):187-203. PubMed ID: 21083462
[TBL] [Abstract][Full Text] [Related]
14. New drugs: pitavastatin calcium, vigabatrin, and romidepsin.
Hussar DA; Christian ME
J Am Pharm Assoc (2003); 2010; 50(4):548-51. PubMed ID: 20621877
[No Abstract] [Full Text] [Related]
15. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Ellis L; Pan Y; Smyth GK; George DJ; McCormack C; Williams-Truax R; Mita M; Beck J; Burris H; Ryan G; Atadja P; Butterfoss D; Dugan M; Culver K; Johnstone RW; Prince HM
Clin Cancer Res; 2008 Jul; 14(14):4500-10. PubMed ID: 18628465
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors in the treatment of lymphoma.
Lemoine M; Younes A
Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
[TBL] [Abstract][Full Text] [Related]
17. Deal watch: Celgene acquires Gloucester pharmaceuticals, gaining approved HDAC inhibitor.
Nat Rev Drug Discov; 2010 Feb; 9(2):94. PubMed ID: 20118955
[No Abstract] [Full Text] [Related]
18. [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors].
Zirlik K; Nashan D; Veelken H
Pharm Unserer Zeit; 2010 May; 39(3):190-6. PubMed ID: 20425773
[No Abstract] [Full Text] [Related]
19. [Histone deacetylase inhibitors: highlight on epigenetic regulation].
Pécuchet N; Cluzeau T; Thibault C; Mounier N; Vignot S
Bull Cancer; 2010 Aug; 97(8):917-35. PubMed ID: 20483706
[TBL] [Abstract][Full Text] [Related]
20. HDAC modulation and cell death in the clinic.
Dell'Aversana C; Lepore I; Altucci L
Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
